Takeda and Metabolon Initiate Research Collaboration

News Apr 18, 2012

Metabolon, Inc. has announced that Metabolon and Takeda Pharmaceutical Company Limited have formed a multiyear research alliance that will focus on discovering therapeutic targets and biomarkers.

Metabolon has developed a proprietary analytical platform and software for biomarker discovery using metabolomics to accelerate drug discovery and development by accurately measuring the spectrum of biochemical changes in biological samples, and mapping these changes to their corresponding metabolic pathways.

Metabolon will apply its platform to discover and validate targets, and identify novel pharmacodynamic biomarkers for translation into the clinic.

Metabolon’s CEO John Ryals said, “We are excited about the prospect of collaborating with Takeda to accelerate its research programs. Metabolon has built a unique platform and has accumulated a vast amount of institutional knowledge in the field of metabolome analysis. We believe that integrating metabolomic profiling into Takeda’s R&D programs may lead to novel therapies and more informed decisions.

1 in 3 U.S. Adults May Be Using Medications That Have Potential to Cause Depression

News

A new study from University of Illinois at Chicago researchers suggests that more than one-third of U.S. adults may be using prescription medications that have the potential to cause depression or increase the risk of suicide.

Sartorius Stedim Biotech and Siemens Sign Automation Agreement

News

Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.

Algorithm Helps Diagnose Zika Using Biomarkers

News

A platform that can diagnose several diseases with a high degree of precision using metabolic markers found in patients’ blood has been developed by scientists at the University of Campinas (UNICAMP) in Brazil.